Logo

Fresenius Kabi's Idacio (adalimumab- biosimilar) Receives EU's Marketing Approval in Rheumatology- Gastroenterology and Dermatology

Share this

Fresenius Kabi's Idacio (adalimumab- biosimilar) Receives EU's Marketing Approval in Rheumatology- Gastroenterology and Dermatology

Shots:

  • The approval is based on its non-inferiority data consisting of its PK- efficacy- safety- immunogenicity data with the reference product in analytical- preclinical and clinical data trials
  • Fresenius Kabi has a portfolio consisting of generic drugs- infusion therapies- biosimilars- and clinical nutrition products focusing on multiple therapy areas
  • Idacio (adalimumab- biosimilar) is a mAb and is indicated for Rheumatoid arthritis (RA)- Juvenile Idiopathic Arthritis- Axial Spondyloarthritis- psoriatic arthritis- plaque psoriasis- adult & pediatric Crohn’s disease and ulcerative colitis

Ref: Fresenius Kabi | Image: Behance

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions